References
- Cho WC. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007;6:1.
- Marks JE, Phillips JL, Menck HR. The National Cancer Date Base report on the relation of race and national origin to the histology of NPC. Cancer 1998;83:582–8.
- Lee AW, Poon YF, Foo W. Retrospective analysis of 5037 patients with NPC treated during 1976–1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 1992;23:261–70.
- Sanguineti G, Geara FB, Garden AS, Tucker SL, Ang KK, Morrison WH, Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys 1997;37:985–96.
- Lee AW, Tung SY, Chua DT, Ngan RK, Chappell R, Tung R, Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 2010;102:1188–98.
- Wu AM, Senter PD. Arming antibodies: prospects and challenges for immuno-conjugates. Nat Biotechnol 2005;23:1137–46.
- Balhorn R, Hok S, Burke PA, Lightstone FC, Cosman M, Zemla A, Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy: initial application to lymphoma leukemia. Clin Cancer Res 2007;13:5621–8.
- Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007;26:3661–78.
- Fietz T, Thiel E. Antibody therapy in non-Hodgkin's lymphoma: the role of rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab. Recent Results Cancer Res 2007;176:153–63.
- Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. Am J Med Sci 2002;324:14–30.
- Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495–7.
- Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003;9:129–34.
- McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990;348:552–4.
- Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antibodies. Mol Cells 2005;20:17–29.
- Cai X, Garen A. Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries. Proc Natl Acad Sci USA 1995;92:6537–41.
- Allen D, Cumano A, Dildrop R. Timing, genetic requirements and functional consequences of somatic hypermutation during B-cell development. Immunol Rev 1987;96:5–22.
- Dohmen SE, Mulder A, Verhagen QJ, Eijsink C, Frank-vanDijk ME, van der Schoot CE. Production of recombinant Ig molecules from antigen-selected single B cells and restricted usage of Ig-gene segments by anti-D antibodies. J Immunol Methods 2005;298:9–20.
- Shui X, Huang J, Li YH, Xie PL, Li GC. Construction and selection of human Fab antibody phage display library of liver cancer. Hybridoma 2009;28:341–7.
- He X, Li G, Zhu J. Construction and selection of human anti-idiotypic antibody single chain variable fragments or CDR3 fragments of nasopharyngeal carcinoma. J Exp Clin Cancer Res 2004;23:607–15.
- Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996;14:309–14.